spacer
home > events calendar > more about event
PHARMACEUTICAL INDUSTRY EVENTS CALENDAR

TAT 2018 Targeted Anticancer Therapies

European Society for Medical Oncology (ESMO)

5-7 March 2018
Paris Marriott Rive Gauche Hotel & Conference Centre

The constant evolution of early phase development and translational research drove ESMO to enrich its meeting portfolio by acquiring the TAT Congress and providing a discussion platform focusing on new molecular targets and innovative cancer therapeutics.

A prestigious scientific committee, led jointly by G. Giaccone and J. Tabernero, designed a cutting-edge programme, establishing the TAT 2018 Congress as the premier international anticancer drug development meeting bringing together academia, industry, clinicians, researchers, scientists and regulators.

The goals and the design of phase 1 studies have changed from just safety/toxicity to now include clinical activity/response and biomarker research. This new phase 1 paradigm has already led to rapid, conditional, approval of several new cancer therapeutics showing outstanding clinical activity in early-phase studies.

TAT focuses on early-phase development and translational research. The programme will cover targeted agents, immuno-oncology and combinations involving such agents. We hope to see you at TAT 2018!

phone +41 (0)91 973 19 00
email esmo@esmo.org
web www.esmo.org
 
Print this page
Send to a friend
   
Banner of Bio Trinity_Events_Page on Samedan
spacer
Industry Events

Highly Potent Active Pharmaceutical Ingredients (HPAPI)

13-14 May 2019, Copthorne Tara Hotel, London, UK

SMi is delighted to announce its 3rd Annual Highly Potent Active Pharmaceutical Ingredients conference coming to London on the 13th-14th May 2019. The HPAPI global market has developed rapidly in the past year and is continuing to expand into the future, with over a quarter of drugs in development worldwide being classified as highly potent. As a result, there is a growing demand for both pharmaceutical and contracted manufacturers to adapt to the evolving HPAPI landscape.
More info >>

White Papers

Clinical Trial-Specific Travel Programs as a Patient Retention Tool

For many patients, participating in a clinical trial is a major endeavor. Depending on the protocol requirements, study visits can be exhausting. There are a number of reasons why a patient may choose to participate in a trial only to drop out. Conversely, there are several approaches to proactively try to prevent this from happening. There are various methods professionals implement for patient retention. This white paper explores patient travel services as one patient retention strategy.
More info >>


News and Press Releases

International biomed specialist appoints WHP to deliver key expansion project

New state of the art cleanroom facilities will enable a leading international gene and cell therapy company to expand its bioprocessing operations and manufacturing capabilities.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement